98 related articles for article (PubMed ID: 17217711)
1. [The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia].
Dang AM; Liu GZ; Zhang YH; Chen GL;
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):882-5. PubMed ID: 17217711
[TBL] [Abstract][Full Text] [Related]
2. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
Dang A; Zhang Y; Liu G; Chen G; Song W; Wang B
J Hum Hypertens; 2006 Jan; 20(1):45-50. PubMed ID: 16281062
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Würzner G; Gerster JC; Chiolero A; Maillard M; Fallab-Stubi CL; Brunner HR; Burnier M
J Hypertens; 2001 Oct; 19(10):1855-60. PubMed ID: 11593107
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
5. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.
Oparil S; Guthrie R; Lewin AJ; Marbury T; Reilly K; Triscari J; Witcher JA
Clin Ther; 1998; 20(3):398-409. PubMed ID: 9663357
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
Neutel JM; Franklin SS; Lapuerta P; Bhaumik A; Ptaszynska A
J Hum Hypertens; 2008 Apr; 22(4):266-74. PubMed ID: 17928878
[TBL] [Abstract][Full Text] [Related]
7. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
Kassler-Taub K; Littlejohn T; Elliott W; Ruddy T; Adler E
Am J Hypertens; 1998 Apr; 11(4 Pt 1):445-53. PubMed ID: 9607383
[TBL] [Abstract][Full Text] [Related]
9. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
Neutel JM; Germino FW; Smith D
J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
[TBL] [Abstract][Full Text] [Related]
10. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
11. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
[TBL] [Abstract][Full Text] [Related]
12. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
Lacourcière Y; Neutel JM; Schumacher H
Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
[TBL] [Abstract][Full Text] [Related]
13. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
Weiss RJ; Stapff M; Lin Y
Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
[TBL] [Abstract][Full Text] [Related]
14. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
[TBL] [Abstract][Full Text] [Related]
15. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension.
Chan JC; Critchley JA; Lappe JT; Raskin SJ; Snavely D; Goldberg AI; Sweet CS
J Hum Hypertens; 1995 Sep; 9(9):765-71. PubMed ID: 8551492
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension].
Zhu JR; Cai NS; Fan WH; Zhu DL; He B; Wu ZG; Ke YN; Guo JX; Ma H; Huang J; Li XL; Chen YZ
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):877-81. PubMed ID: 17217710
[TBL] [Abstract][Full Text] [Related]
17. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
[TBL] [Abstract][Full Text] [Related]
18. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
[TBL] [Abstract][Full Text] [Related]
19. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
[TBL] [Abstract][Full Text] [Related]
20. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.
Rayner BL; Trinder YA; Baines D; Isaacs S; Opie LH
Am J Hypertens; 2006 Feb; 19(2):208-13. PubMed ID: 16448895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
